Skip to content

Knowledge builds confidence.

Confidence empowers decisions.

Make It Make Sense (MIMS) is here to help you understand clinical trials and explore your options so you can have more informed conversations and make decisions that are right for you.

Understand

Understand

Clear, easy-to-understand information about HER2-positive early breast cancer.

Explore

Explore

Learn about clinical trials and how research is advancing treatment options.

Ask

Ask

Get questions to help you start conversations with your healthcare team.

Empower

Empower

Feel confident making informed decisions about your care and your future.

This Months Focus

This Month’s Focus

Understanding HR+/HER2-Negative Breast Cancer

HR+/HER2-negative breast cancer is a subtype of breast cancer defined by two important biomarkers: hormone receptors (HR) and HER2.

Hormone Receptor-Positive [HR+]:
HR+ breast cancer cells have receptors that can use hormones such as estrogen and progesterone to grow.

HER2-Negative [HER2- ]:
HER2-negative breast cancer cells do not have higher-than-normal levels of the HER2 protein.

What this means for you:
Knowing your breast cancer subtype gives you information you can use when talking with your healthcare team about your care and your options.

Know Your Breast Cancer Subtype:
Learn what HR+, HER2-, and other biomarker results may tell you about your breast cancer and why this information matters.

Why Are Clinical Trials Important?

Clinical trials help researchers discover new ways to:

Improve treatment effectiveness
Reduce side effects
Personalize care
Improve quality of life
Advance future standards of care

Clinical trials are an important option for many people and may be available at different stages of breast cancer.

Treatment options may include:

Clinical Trials | Surgery | Chemotherapy (when appropriate) | HER2-targeted therapies | Radiation therapy | Ongoing follow-up care

Did You Know?

Clinical trials for HR+/HER2-negative breast cancer are studying new ways to address how cancer may continue to grow after previous treatments. Researchers are exploring new targets and treatment combinations to expand future options.
Ask Your Healthcare Team:
“Do we have the biomarker information we need for the decisions we’re making now?”

Biomarker Education:

Learning More About Your Cancer
Biomarker testing looks for characteristics of your cancer that may provide information about how it grows and behaves.

ER – Whether cancer cells have estrogen receptors
PR – Whether cancer cells have progesterone receptors
HER2 – Whether cancer cells have higher-than-normal levels of HER2

Depending on your diagnosis and treatment history, your healthcare team may discuss whether additional testing could provide useful information.

our-promise

Our Promise

MIMS is designed to provide clear, unbiased educational information about clinical trials so you can have informed conversations with your healthcare team.

“Participation in a clinical trial is always your choice.”

EV407 Study

Phase I/Ib | NCT07604571
A clinical trial studying investigational IEV407 alone or with endocrine therapy in people with advanced HR+/HER2-negative breast cancer.

Researchers are studying safety, dosing, side effects, and early signs of treatment response.

Learn More » novartis.com/clinicaltrials/study/NCT07604571

GVV858 Study

Phase I/II | NCT07288359
A clinical trial studying investigational GVV858 alone or with endocrine therapy in people with advanced HR+/HER2-negative breast cancer and certain other advanced solid tumors.

Researchers are studying safety, suitable doses, and how participants’ cancers respond during treatment.

Learn More » novartis.com/clinicaltrials/study/NCT07288359

BC-303 (EmpowHER-303) Study

Trial Evaluating Zanidatamab in Metastatic HER2-Positive Breast Cancer (NCT06435429)
 
Designed to evaluate investigational treatment approaches for individuals with HER2-positive breast cancer.
 
Metastatic means breast cancer has spread to another part of the body.
 
Learn More » myher2trial.com

BC-208 (EmpowHER-208) Study

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer (EmpowHER 208) (NCT07102381)
 
Exploring additional treatment strategies that may improve outcomes for eligible patients diagnosed with HER2-positive early breast cancer. 
 
Neoadjuvant means treatment given before surgery.
 

Talk with your healthcare team to see if a clinical trial may be right for you.

More About Clinical Trials →

Explore Trusted Resources

Start here to learn more about your cancer and clinical trial options.

Learn More About Your Cancer

Learn More About Your Cancer

Understand your diagnosis, treatment options, and what to expect.

Explore Clinical Trial Opportunities

Explore Clinical Trial Opportunities

Learn how clinical trials work and how they may help you or others.

 

Find Questions to Ask Your Doctor

Find Questions to Ask Your Doctor

Helpful questions to guide your next conversation.

Learn About Clinical Trial Participation

Learn About Clinical Trial Participation

Understand the process, your rights, and what to expect.

Thank You to Our Sponsors

Make It Make Sense (MIMS) is made possible through the generous support of our sponsors, whose commitment helps expand access to trusted cancer and clinical trial education.

JAZZ_BIG-8c2ac29f